The results from 4D Pharma Plc's Phase I/II open-label trial of “live biotherapeutics” candidate MRx0518 in combination with Merck & Co., Inc.’s blockbuster Keytruda (pembrolizumab), suggest it could help refractory patients respond to cancer immunotherapy once again.
The Leeds, UK-based micro-cap company has been developing live bacteria therapies to treat a range of immune-related diseases (including irritable bowel syndrome and Crohn’s disease) since 2014, but a lack...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?